GRDN
GRDN
Guardian Pharmacy Services, Inc.Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q4-2025 | $397.62M ▲ | $27.85M ▼ | $20.92M ▲ | 5.26% ▲ | $0.33 ▲ | $42.34M ▲ |
| Q3-2025 | $377.43M ▲ | $58.37M ▲ | $9.82M ▲ | 2.6% ▼ | $0.16 ▲ | $23.61M ▲ |
| Q2-2025 | $344.33M ▲ | $55.57M ▲ | $9.03M ▼ | 2.62% ▼ | $0.15 | $18.25M ▼ |
| Q1-2025 | $329.31M ▼ | $51.34M ▲ | $9.45M ▼ | 2.87% ▼ | $0.15 ▼ | $18.54M ▼ |
| Q4-2024 | $338.57M | $50.35M | $11.94M | 3.53% | $0.2 | $21.8M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q4-2025 | $65.62M ▲ | $412.66M ▲ | $194.73M ▲ | $205.76M ▲ |
| Q3-2025 | $36.49M ▲ | $390.04M ▲ | $194.54M ▲ | $183.76M ▲ |
| Q2-2025 | $18.82M ▲ | $356.33M ▲ | $176.66M ▲ | $169.56M ▲ |
| Q1-2025 | $14M ▲ | $334M ▲ | $170.78M ▼ | $156.09M ▲ |
| Q4-2024 | $4.66M | $320.81M | $170.83M | $142.67M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q4-2025 | $21.27M ▲ | $34.6M ▲ | $-4.36M ▲ | $-1.11M ▲ | $29.13M ▲ | $30.37M ▲ |
| Q3-2025 | $9.59M ▲ | $28.17M ▲ | $-8.97M ▲ | $-1.53M ▲ | $17.67M ▲ | $22.96M ▲ |
| Q2-2025 | $8.83M ▼ | $19.94M ▲ | $-13M ▼ | $-2.11M ▲ | $4.82M ▼ | $15.63M ▲ |
| Q1-2025 | $9.27M ▼ | $17.55M ▼ | $-5.54M ▲ | $-2.67M ▲ | $9.34M ▲ | $11.74M ▼ |
| Q4-2024 | $11.94M | $22.34M | $-6.62M | $-48.27M | $-32.56M | $17.84M |
Revenue by Products
| Product | Q1-2025 | Q2-2025 | Q3-2025 | Q4-2025 |
|---|---|---|---|---|
Corporate Segment | $330.00M ▲ | $340.00M ▲ | $380.00M ▲ | $400.00M ▲ |
Q4 2025 Earnings Call Summary
Read Call Summary5-Year Trend Analysis
A comprehensive look at Guardian Pharmacy Services, Inc.'s financial evolution and strategic trajectory over the past five years.
Guardian combines a sizable, recurring revenue base with clear profitability, strong cash generation, and a conservative balance sheet featuring low debt and ample liquidity. Its specialized focus on assisted living and behavioral health, supported by proprietary technology and a hybrid local‑plus‑national model, creates a differentiated service offering. The company’s ability to convert earnings into cash, reinvest in operations, and still grow its cash balance underscores solid financial discipline and operational execution.
Key risks stem from operating in a low‑margin, highly regulated healthcare niche that is exposed to reimbursement changes, regulatory shifts, and consolidation among long‑term care providers. Intangible assets and goodwill tied to acquisitions could be vulnerable if acquired units underperform. High overhead relative to revenue leaves limited margin for error if volumes or pricing come under pressure. In addition, heavy reliance on internal technology and data systems means that execution missteps, cybersecurity issues, or lagging innovation versus larger competitors could erode advantages over time.
Based on the available data, Guardian appears financially sound and competitively well positioned within its chosen niches, with strong cash flow and a balance sheet that can support continued investment and selective growth. Future performance will likely depend on its ability to maintain reimbursement levels, deepen relationships with long‑term care facilities, keep innovating its technology and analytics platforms, and integrate any additional acquisitions smoothly. With only one year of detailed financials, visibility into long‑term trends is limited, but the current snapshot suggests a stable platform with both opportunities and execution risks ahead.
About Guardian Pharmacy Services, Inc.
https://guardianpharmacy.comGuardian Pharmacy Services, Inc., a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q4-2025 | $397.62M ▲ | $27.85M ▼ | $20.92M ▲ | 5.26% ▲ | $0.33 ▲ | $42.34M ▲ |
| Q3-2025 | $377.43M ▲ | $58.37M ▲ | $9.82M ▲ | 2.6% ▼ | $0.16 ▲ | $23.61M ▲ |
| Q2-2025 | $344.33M ▲ | $55.57M ▲ | $9.03M ▼ | 2.62% ▼ | $0.15 | $18.25M ▼ |
| Q1-2025 | $329.31M ▼ | $51.34M ▲ | $9.45M ▼ | 2.87% ▼ | $0.15 ▼ | $18.54M ▼ |
| Q4-2024 | $338.57M | $50.35M | $11.94M | 3.53% | $0.2 | $21.8M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q4-2025 | $65.62M ▲ | $412.66M ▲ | $194.73M ▲ | $205.76M ▲ |
| Q3-2025 | $36.49M ▲ | $390.04M ▲ | $194.54M ▲ | $183.76M ▲ |
| Q2-2025 | $18.82M ▲ | $356.33M ▲ | $176.66M ▲ | $169.56M ▲ |
| Q1-2025 | $14M ▲ | $334M ▲ | $170.78M ▼ | $156.09M ▲ |
| Q4-2024 | $4.66M | $320.81M | $170.83M | $142.67M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q4-2025 | $21.27M ▲ | $34.6M ▲ | $-4.36M ▲ | $-1.11M ▲ | $29.13M ▲ | $30.37M ▲ |
| Q3-2025 | $9.59M ▲ | $28.17M ▲ | $-8.97M ▲ | $-1.53M ▲ | $17.67M ▲ | $22.96M ▲ |
| Q2-2025 | $8.83M ▼ | $19.94M ▲ | $-13M ▼ | $-2.11M ▲ | $4.82M ▼ | $15.63M ▲ |
| Q1-2025 | $9.27M ▼ | $17.55M ▼ | $-5.54M ▲ | $-2.67M ▲ | $9.34M ▲ | $11.74M ▼ |
| Q4-2024 | $11.94M | $22.34M | $-6.62M | $-48.27M | $-32.56M | $17.84M |
Revenue by Products
| Product | Q1-2025 | Q2-2025 | Q3-2025 | Q4-2025 |
|---|---|---|---|---|
Corporate Segment | $330.00M ▲ | $340.00M ▲ | $380.00M ▲ | $400.00M ▲ |
Q4 2025 Earnings Call Summary
Read Call Summary5-Year Trend Analysis
A comprehensive look at Guardian Pharmacy Services, Inc.'s financial evolution and strategic trajectory over the past five years.
Guardian combines a sizable, recurring revenue base with clear profitability, strong cash generation, and a conservative balance sheet featuring low debt and ample liquidity. Its specialized focus on assisted living and behavioral health, supported by proprietary technology and a hybrid local‑plus‑national model, creates a differentiated service offering. The company’s ability to convert earnings into cash, reinvest in operations, and still grow its cash balance underscores solid financial discipline and operational execution.
Key risks stem from operating in a low‑margin, highly regulated healthcare niche that is exposed to reimbursement changes, regulatory shifts, and consolidation among long‑term care providers. Intangible assets and goodwill tied to acquisitions could be vulnerable if acquired units underperform. High overhead relative to revenue leaves limited margin for error if volumes or pricing come under pressure. In addition, heavy reliance on internal technology and data systems means that execution missteps, cybersecurity issues, or lagging innovation versus larger competitors could erode advantages over time.
Based on the available data, Guardian appears financially sound and competitively well positioned within its chosen niches, with strong cash flow and a balance sheet that can support continued investment and selective growth. Future performance will likely depend on its ability to maintain reimbursement levels, deepen relationships with long‑term care facilities, keep innovating its technology and analytics platforms, and integrate any additional acquisitions smoothly. With only one year of detailed financials, visibility into long‑term trends is limited, but the current snapshot suggests a stable platform with both opportunities and execution risks ahead.

CEO
Fred Burke
Compensation Summary
(Year 2025)
Upcoming Earnings
ETFs Holding This Stock
VTS.AX
Weight:0.00%
Shares:921.81K
XSU.TO
Weight:0.03%
Shares:531.82K
FDLS
Weight:1.11%
Shares:50.10K
Summary
Showing Top 3 of 102
Ratings Snapshot
Rating : B+
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
BROWN ADVISORY INC
Shares:1.76M
Value:$64.96M
BLACKROCK, INC.
Shares:1.74M
Value:$64.36M
VANGUARD GROUP INC
Shares:1.35M
Value:$49.98M
Summary
Showing Top 3 of 146

